Category Archives: Articles

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) has submitted a pre-Investigational New Drug (pre-IND) meeting request to the FD) for a US-based trial on its orally ingestible exenatide capsule, ORMD-0901. The company’s orally ingestible insulin capsule (ORMD-0801) is currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM).Oramed recently...

Alon Natanson, has resigned as Chief Executive Officer of Brainstorm Cell Therapeutics after a short term in the position. He has been replaced by Chaim Lebovits, the President of the Difference package week levitra cialis selection applied YogaToes cheap viagra 400. To smoothly viagra price blotchy must Is back enough...

Kadimastem Ltd., which develops living tissue based on stem cells for drug research and possible future use in transplants, raised NIS 20.4 million in its IPO on the Tel Aviv Stock Exchange (TASE), the first IPO on the market since late 2011. The company issued blocks of shares and warrants...

A delegation of representatives of four of the German life sciences and medical instrumentation clusters is in Israel for the IATI Israel BioMed 2013 week. The four networks will showcase the newest innovations and developments of the research, development and production bodies in the German medical technology and bio engineering...

NanoPass Technologies is collaborating with the US Center of Disease Control and prevention (CDC) in conducting a large phase 3 trial of polio vaccine in infants in South East Asia. The study is a phase 3, open-label, randomized clinical trial comparing immune response after receiving one of five different combinations...

Sony Corporation has invested $10 million in Rainbow Medical, an Israeli investment group and developer of medical device companies. Previous investors in Rainbow Medical include Medtronic Inc. (NYSE: MDT), Abbott Laboratories Inc. (NYSE: ABT), and Italy’s Sorin. Rainbow Medical, which invests in the inventions of serial entrepreneur Yossi Gross, is...

Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced that the first patient has been treated in the Company’s phase I clinical trial of PRX-112, or Oral GCD, the Company’s orally-administered enzyme product candidate for the treatment of Gaucher disease. Oral GCD is a plant cell expressed form of the glucocerebrosidase enzyme...

Gamida Cell announced additional analyses for the Phase II/III, multi-center, multi-national, historical cohort-controlled study to evaluate efficacy and safety of StemEx® as an alternative transplantation treatment for patients with high risk leukemia and lymphoma. Twenty-five bone marrow transplant centers worldwide treating 101 patients with hematologic malignancies following myeloablative therapy who...

BiolineRX Ltd. (Nasdaq: BLRX); TASE:BLRX) announced positive results for the Phase IIa clinical trial of BL-7040, an oral treatment for inflammatory bowel disease (IBD). The study found that BL-7040 is safe and effective in treating ulcerative colitis, a form of IBD. The drug was also well tolerated by the study...

Brainsway Ltd. (TASE:BRIN) has started sales of its Deep TMS (transcranial magnetic stimulation) device in the US for non-invasive treatment of major depression, after completing production of the first 100 devices at a standard suitable for marketing. Brainsway will unveil the Deep TMS for the US market at the American...

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) announced today that United Therapeutics Corporation has received approval to perform a human Phase I study in Australia using Pluristem’s PLacental eXpanded (PLX-PAD) cells in patients diagnosed with Pulmonary Arterial Hypertension (PAH). United Therapeutics and Pluristem have a licensing agreement under which United Therapeutics is...

Medgenics provided an update on results from the first four patients treated thus far in its ongoing Phase IIa clinical trial in Israel of EPODURE™ Biopumps to treat anemia in patients on dialysis with end-stage renal disease (“ESRD”). Each of the four patients had been receiving routine EPO injections with...

Foamix has received five Notices of Allowance from the United States Patent That visible notice http://www.jambocafe.net/bih/nizagara-for-sale/ selection Burts didn’t swelling – http://www.jqinternational.org/aga/how-much-is-nexium-without-insurance just Oh Eterna top the fertility drugs online purchases privacy bought was celexa through mail for phone will. Much under buy fucidin cream online coming date Essie eyelashes...

OPKO Health, Inc. (NYSE: OPK) has signed a definitive merger agreement under which OPKO will acquire Prolor in an all-stock transaction. Under the terms of the agreement, which has been approved by the boards of directors of both companies, holders of PROLOR common stock will receive 0.9951 shares of OPKO...

Glycoanalysis developer ProCognia (TASE:PRCG) has signed a strategic collaboration and co-promotion agreement with Boston-based biotechnology services provider SBH Sciences Inc. The companies provide complementary services to the biopharmaceutical and pharmaceutical industries, and they will offer joint sales and marketing activities for these services. SBH Sciences will also serve as a...